Article
Robust central reduction of amyloid-β in humans with an orally available, non-peptidic β-secretase inhibitor.
The Journal of neuroscience : the official journal of the Society for Neuroscience - 16 Nov 2011
May Patrick C, Dean Robert A, Lowe Stephen L, Martenyi Ferenc, Sheehan Scott M, Boggs Leonard N, Monk Scott A, Mathes Brian M, Mergott Dustin J, Watson Brian M, Stout Stephanie L, Timm David E, Smith Labell Elizabeth, Gonzales Celedon R, Nakano Masako, Jhee Stanford S, Yen Mark, Ereshefsky Larry, Lindstrom Terry D, Calligaro David O, Cocke Patrick J, Greg Hall D, Friedrich Stuart, Citron Martin, Audia James E
Abstract excerpt
According to the amyloid cascade hypothesis, cerebral deposition of amyloid-β peptide (Aβ) is critical for Alzheimer's disease (AD) pathogenesis. Aβ generation is initiated when β-secretase (BACE1) cleaves the amyloid precursor protein. For more than a decade, BACE1 has been a prime target for designing drugs to prevent or treat AD. However, development of such agents has turned out to be extremely challenging,...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.